Early Detection of Alzheimer's Disease Pathology for Clinical Diagnosis and Treatment Trials: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Michael Weiner
Professor of Medicine, Radiology and Psychiatry, University of California San Francisco; Director, MRS Unit, DVA Medical Center San Francisco
Early Detection of Alzheimer's Disease Pathology for Clinical Diagnosis and Treatment Trials: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Michael W. Weiner, M.D.
Center for Imaging of Neurodegenerative Diseases
San Francisco VA Medical Center
Professor of Radiology, Medicine, Psychiatry and Neurology, University of California, San Francisco
Principle Investigator: Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Michael W. Weiner, M.D.

Disclosures

Scientific Advisory Boards
Pfizer
BOLT Inter-national

Consulting
Pfizer
Janssen
KLJ Associates
Easton Associates
Harvard University
inThought
B&N Associates, LLC
INC Research, Inc.
University of California, Los Angeles
Alzheimer’s Drug Discovery Foundation

Honoraria
Pfizer
Tohoku University
Danone Trading, BV

Commercial Research Support
Merck
Avid

Stock Options
Elan
Synarc

ADNI Support
Abbott
Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation
Anonymous Foundation
Innogenetics
Wyeth
Schering Plough
Roche

Bayer Healthcare
BioClinica, Inc. (ADNI2)
Bristol-Myers Squibb
Cure Alzheimer’s Fund
Eisai
Elan
GeneNetwork Sciences
Pfizer
GE Healthcare
GlaxoSmithKline
Pfizer, Inc.
Novartis
Merck
MCP
Eli Lilly & Company
Johns Hopkins
Johnson & Johnson
Astra Zeneca
Genentech
Synarc

Funding for Travel
ADPD
CTAD ANY Congres (Clinical Trials on Alzheimer’s Disease)
University of California, Los Angeles
Travel eDreams, Inc.
Paul Sabatier University
Tohoku University
Novartis
Neuroscience School of Advanced Studies (NSAS)
Danone Trading, BV
MCI Group, France
University of California, San Diego; ADNI
THE OVERALL MESSAGE

• Advances in medical research are heavily depending on technological progress

• Successful research combines biological understanding with technological expertise

• Medical research is increasingly collaborative: data collectors/data analyzers

• There must be widespread sharing of scientific data!
WHAT DO WE KNOW ABOUT ALZHEIMER’S DISEASE

- Clinical presentation
- Pathology
- Misfolded proteins and neurodegeneration
- The “amyloid cascade hypothesis”
  - Recent evidence, role of tau, cell to cell spread
- Treatment failures
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Thorlakur Jonsson¹, Jasvinder K. Atwal², Stacy Steinberg¹, Jon Snaedal³, Palmi V. Jonsson³, Sigurbjorn Bjornsson³, Hreinn Stefansson¹, Patrick Sulem¹, Daniel Gudbjartsson¹, Janice Maloney², Kwame Hoyte², Amy Gustafson², Yichin Liu², Yanmei Lu², Tushar Bhangale³, Robert R. Graham², Johanna Huttonlocher¹, Gyda Bjornsdottir¹, Ole A. Andreassen⁵, Erik G. Jönsson⁶, Aarno Palotie⁷, Timothy W. Behrens², Olafur T. Magnusson¹, Augustine Kong¹, Unnur Thorsteinsdottir¹,², Ryan J. Watts² & Kari Stefansson¹,²
ATTENTION!

The entire presentation will be provided to registered attendees only at the conference!

To view the rest of this exciting presentation and many more please register for the conference at

www.gtcbio.com